Abstract
The global burden associated with hepatitis C virus (HCV) infection has prompted a scale-up of antiviral therapy. Hitherto, no data existed on the impact of scaling-up on the characteristics of treated populations or on sustained viral response (SVR) rates. We assessed the country-wide scale-up of antiviral therapy in Scotland, a country which nationally monitors uptake of and response to HCV treatment METHODS: Data for patients initiated on combined pegylated interferon and ribavirin therapy at 13 specialist HCV clinics in 2001-2010 were extracted from the Scottish HCV Clinical Database (n=3895). Patient characteristics included age, genotype, PWID (people who inject drugs) status, prison referral, and diagnosed cirrhosis. Temporal trends in covariates and adjusted effects on SVR were examined via mixed-effects regression.
Original language | English |
---|---|
Pages (from-to) | 262-268 |
Number of pages | 7 |
Journal | Journal of Hepatology |
Volume | 62 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2015 |
Keywords
- Antiviral therapy
- Hepatitis C virus
- Pegylated interferon
- Sustained viral response
ASJC Scopus subject areas
- Hepatology
Fingerprint
Dive into the research topics of 'What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?'. Together they form a unique fingerprint.Profiles
-
Dillon, John
- Respiratory Medicine and Gastroenterology - Clinical Professor (Teaching and Research) of Hepatology and Gastroenterology
Person: Academic